Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 — Inside the Issue of Adverse Event Management

Prof Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The University of Texas MD Anderson Cancer Center in Houston, discuss strategies to manage ocular toxicities associated with antibody-drug conjugates and other cancer therapies.
CME information and select publications here (researchtopractice.com/InsideTheIssue2024/Ocul…).